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About 50% of male diabetic patients have erectile dysfunction (ED),
which is considered as the vascular and neuropathic complications.
Vascular endothelial growth factor (VEGF) has been extensively
documented for its pathogenic signiﬁcance in different complications
of diabetes andwe reported that VEGF signaling is greatly diminished in
penis in a rat model of type II diabetes. The present study used 3 weeks
duration of streptozotocin (STZ)-induced diabetic (DM) rat model to
assess the VEGF expression with NO system in penile tissue and
concomitantly the effects of endothelin antagonismhas been studied on
these changes. Male Sprague–Dawley rats were administered citrate
saline vehicle or STZ (65 mg/kg IP). One week after the injection,
animals were separated into those receiving endothelin-A/B (ET-A/B)
dual receptor antagonist (SB209670, 1 mg/kg/day), endothelin-A (ET-A)
receptor antagonist (TA-0201, 1 mg/kg/day) or saline for 2 weeks by
osmotic mini pump. The local ET-1 level in DM penis was higher by 20%
than that in non-DM rats. A 30% decrease in VEGF expression in penile
tissue was seen in DM rats. Penile NO and eNOS levels were decreased in
DM rats; greatly restored by ET-A receptor antagonist while unchanged
by ET-A/B dual antagonist. iNOS was not signiﬁcantly changed in penile
tissues among non-DM, DM and ET-A antagonist treated groups. Thus,
we conclude that (1) VEGF and pAkt were downregulated in type 1 DM
penis, and that (2) the ET-A antagonist was potentially effective in
reversing the decreased NO and eNOS levels in DM penis than those by
ET-A/B dual antagonist.
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Aim: To elucidate the pathophysiological signiﬁcance of the endog-
enous oxidized LDL (oxLDL) blocker, which was originally described as
an endothelium-derived secreted protein Del-1 (developmental endo-
thelial locus-1). Background: oxLDL can potentiate the induction of foam
cell formation and inﬂammatory responses, the processes which are
believed to be integral to atherogenesis. However, no endogenous
proteins, which interfere with oxLDL binding to its receptors, have been
identiﬁed. Methods: Interaction between oxLDL and Del-1 was exam-
ined in a cell-free system by ELISA. Inhibition of binding and action of
oxLDL was examined with CHO cells expressing LOX-1 and with COS-7
cells transfected with scavenger receptors. Cultured human umbilical
vein endothelial cells (HUVEC) and THP-1 were also used to analyze the
inhibitory effects of Del-1 on oxLDL action. Results: We found that Del-1
selectively bound to oxLDL, but not to native LDL. Del-1 inhibited the
uptake of DiI-labeled oxLDL (DiI-oxLDL) by LOX-1 expressed in COS-7,
but did not inhibit DiI-labeled native LDL uptake by LDL receptor. Del-1
inhibited DiI-oxLDL binding to other oxLDL receptors aswell, such as SR-
A and CD36. In addition, Del-1 inhibited DiI-oxLDL uptake byHUVEC and
THP-1-derived macrophages. Site-directed mutagenesis revealed that
two arginine residues in Del-1 were crucial for the binding of oxLDL.
Furthermore, Del-1 suppressed oxLDL-induced signal transduction in
LOX-1-expressing CHO cells. In HUVEC, Del-1 also suppressed oxLDL-
induced signaling and endothelin-1 secretion. Thus, we demonstrated
that Del-1 is an endogenous protein which protects cells from oxLDL
actions. Conclusion: We identiﬁed, for the ﬁrst time, an endogenous
oxLDL blocker which may play a regulatory role in interfering
progression of atherosclerosis.
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Purpose: Endothelin-1 contributes to endothelial dysfunction in
patients with atherosclerosis and type 2 diabetes. In healthy arteries the
ETA receptormediates themain part of the vasoconstriction induced by
endothelin-1 while the ETB receptor mediates vasodilatation. The ETB
receptor expression is upregulated in atherosclerosis and may thereby
contribute to the vasoconstrictor tone and development of endothelial
dysfunction. The aim of the present study was to compare the
effects of selective ETA and dual ETA/ETB blockade on endothelial
function in patients with type 2 diabetes and coronary artery disease.
Methods: Twelve patients were included in this cross-over study with
blinded evaluation. Forearm blood endothelium-dependent and endo-
thelium-independent vasodilatation was assessed by venous occlusion
plethysmography during intra-arterial infusions of serotonin and nitro-
prusside, respectively, before and after 60 min of intra-arterial infusion of
either the selective ETA antagonist BQ123 or the combination of BQ123
and the ETB antagonist BQ788. Changes between the two treatments
were compared using 2-way analysis of variance. Results: Dual ETA/ETB
receptor blockade increased baseline forearm blood ﬂow by 30± 14%
(P b 0.01) whereas selective ETA blockade did not (14 ± 8%). Both
selective ETA blockade and dual ETA/ETB blockade induced a 2-fold
increase in endothelium-dependent vasodilatation (P b 0.001). The
improvement in endothelium-dependent vasodilatation did not differ
between the two treatment strategies. Both treatments improved the
endothelium-independent vasodilatation. Conclusions: Both selective
ETA and dual ETA/ETB improve endothelial function in patients with
type 2 diabetes and coronary artery disease. Addition of ETB to ETA
receptor blockade increases basal blood ﬂow but does not additionally
improve endothelial function.
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Background: Statins reduce the incidence of cardiovascular events in
patientswith acutemyocardial infarction (AMI). Although all statins are
equally effective in secondary prevention, there might be certain
differences in the effects of lipophilic and hydrophilic statins and its
associationwith oxidative stress levels in AMI patients remains unclear.
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